Oxford Asset Management’s Protalix BioTherapeutics PLX Stock Holding History

Oxford Asset Management’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-4,214	Closed	-$25K	–	1809
2017 Q3	$25K	Sell	4,214 -64,566	-94%	-$414K	﹤0.01%	1501
2017 Q2	$576K	Buy	+68,780	New	+$646K	0.01%	1063
2015 Q3	–	Sell	-1,017	Closed	-$20K	–	703
2015 Q2	$20K	Buy	+1,017	New	+$21.1K	﹤0.01%	647
2015 Q1	–	Sell	-8,608	Closed	-$162K	–	722
2014 Q4	$162K	Buy	+8,608	New	+$185K	﹤0.01%	632

Other funds holding PLX

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

HCM

Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

MIH

Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Oxford Asset Management's PLX Position: Q4 2017 in Review

Oxford Asset Management sold out of Protalix BioTherapeutics (PLX) in Q4 2017, closing a stake of 4,214 shares — an estimated $25K sold.

Oxford Asset Management first reported a position in PLX in Q4 2014 and held it in 4 quarters. The position peaked at $576K in Q2 2017. 36 funds tracked by Wall St. Rank hold PLX as of Q4 2017.

Oxford Asset Management reported no remaining Protalix BioTherapeutics position as of Q4 2017 after selling out during the quarter.
Oxford Asset Management sold 4,214 Protalix BioTherapeutics shares in Q4 2017, an estimated $25K.
Oxford Asset Management first reported a position in Protalix BioTherapeutics in Q4 2014 and held it in 4 quarters.
Oxford Asset Management's Protalix BioTherapeutics position peaked at $576K in Q2 2017.
36 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q4 2017.

Based on Oxford Asset Management's 13F filing for Q4 2017, filed 13 Feb 2018.